Switching from bio-originator Humira to a biosimilar peaked in April 2024 – the month an important formulary change took effect – and remains higher than 2023, suggesting growing adoption of biosimilars. More than 1 in 8 patients who initiated a biosimilar...
Truveta and collaborators partnered on a new large-scale study that considers the potential benefits of GLP-1 RA for AUD, among those with diabetes and/or obesity. Using a target trial emulation framework, researchers analyzed Truveta Data and compared adults with...
Timely receipt of the MMR vaccine for children has been declining since 2021, with just 76.9% of children receiving the MMR vaccine in 2024 on time. The odds of non-vaccination by age two for measles were higher among male children, children in rural areas, White...
The percentage of uncemented total knee arthroplasties (TKAs) nearly doubled from 5.7% to 10.3% between 2018 and 2024. Readmission and revision rates were similar between cemented and uncemented TKAs. Cemented TKAs were associated with higher rates of stiffness,...
In collaboration with Reuters, Truveta Research explored trends in FDA-approved anti-obesity GLP-1 RA prescriptions among adolescents. Among the 1,265,399 adolescents (aged 12-17 years) in this study, the average rate of first-time AOM semaglutide prescriptions was...
